Moreover, among previously insulin-treated patients, the addition of a one-time 50% extra dose of icodec at first administration, when switching to icodec, resulted in effective glycemic control without transitory fasting hyperglycemia or increased risk of clinically significant hypoglycemia, when compared to patients who switched to once-daily glargine U100. Here, INS is linked to Hypoglycemia.